The use of clozapine for treatment-resistant schizophrenia is well documented. However, not all patients respond to clozapine, and there is a need to have better tools to recognize those who would benefit the most from this medicine. Our aim was to describe a cohort of patients who initiated clozapine treatment between 2014 and 2016 in a public psychiatric institute in Santiago, Chile to identify predictors of clinical response to clozapine.
展开▼
